Oruka Therapeutics builds long-acting psoriasis case as ORKA-001 clearance deepens without redosing

Oruka Therapeutics has strengthened the commercial case for ORKA-001 after psoriasis patients continued moving toward complete skin clearance for months without receiving another dose. In the Phase 2a EVERLAST-A study, 71.4% of patients achieved PASI 100, representing complete skin clearance, by Week 28 compared with 63.5% at Week 16, even though the initial treatment group received its last dose at Week 4. PASI 90 responses climbed to 87.3%, adding evidence that the extended half-life engineered into ORKA-001 could eventually support dosing only once or twice per year rather than every few months. The result gives Oruka Therapeutics a potentially powerful differentiation strategy in the established IL-23 psoriasis market as it prepares for Phase 3 development in the first half of 2027. Investors nevertheless responded cautiously, with Oruka Therapeutics shares falling sharply during afternoon trading as expectations around the highly anticipated durability update were already elevated.

The commercial stakes are increasingly significant because Oruka Therapeutics has already reached a market capitalization of roughly $5.7 billion despite remaining a clinical-stage biotechnology company without product revenue. That valuation reflects substantial expectations that ORKA-001 can combine the strong efficacy associated with IL-23 inhibition with a much longer dosing interval than currently approved biologics. The upcoming Phase 2b EVERLAST-B readout and full 52-week EVERLAST-A results will therefore be critical in determining whether the durability profile can support those expectations before the company commits to pivotal development.

Deepening clearance months after the last dose strengthens ORKA-001’s long-interval treatment proposition

EVERLAST-A enrolled 84 adults with moderate-to-severe plaque psoriasis across 26 sites in the United States and Canada. Participants were randomized three-to-one to receive 600 milligrams of ORKA-001 at Weeks 0 and 4 or placebo, with the placebo group later crossing over to active treatment at Weeks 16 and 20.

The key feature of the latest update is what happened after active dosing stopped. Among the 63 patients originally assigned to ORKA-001, PASI 100 increased from 63.5% at Week 16 to 71.4% at Week 28, while PASI 90 increased to 87.3%. Investigator Global Assessment scores of clear or almost clear were maintained in 84.1% of patients.

That means response depth continued to improve approximately six months after the second induction dose rather than gradually weakening as drug exposure moved farther away from administration. For Oruka Therapeutics, that pattern is central to the product’s intended positioning.

ORKA-001 targets interleukin-23 p19, the same validated inflammatory pathway addressed by several highly successful psoriasis biologics. The company is therefore not trying to persuade physicians that an unfamiliar biological mechanism works. Instead, it is attempting to improve on a proven treatment class by engineering a substantially longer half-life while maintaining deep disease clearance.

Oruka Therapeutics previously reported that ORKA-001 has a human half-life of approximately 100 days. Phase 1 pharmacokinetic data indicated that a single 600-milligram dose maintained concentrations above the company’s estimated effective trough level through Week 52, supporting development toward once- or twice-yearly administration.

The Week 28 clinical results now give that pharmacokinetic argument more practical relevance. Maintaining drug concentrations is useful scientifically, but a commercially meaningful advantage requires patients to remain clear as treatment intervals extend. EVERLAST-A is beginning to provide evidence that the two characteristics may align.

The placebo crossover group also produced a similar early trajectory. Twelve weeks after starting ORKA-001, 40% of crossover patients had reached PASI 100 compared with 42.9% of the original active-treatment group at the equivalent point. That internal consistency provides additional support for the treatment effect, although the study remains relatively small.

Once- or twice-yearly dosing could give Oruka Therapeutics a meaningful edge in a proven psoriasis market

The commercial opportunity rests partly on how ORKA-001 compares with already successful IL-23 therapies. Johnson & Johnson’s Tremfya is administered at Weeks 0 and 4 followed by maintenance dosing every eight weeks in plaque psoriasis, while AbbVie’s Skyrizi is dosed at Weeks 0 and 4 and then every 12 weeks.

ORKA-001 is being designed for maintenance dosing as infrequently as once or twice annually. If that schedule can preserve similarly deep or better skin clearance, patients could move from four to six maintenance injections per year with established therapies toward only one or two.

That difference may sound incremental on paper, but psoriasis is a chronic disease requiring long-term adherence. Reducing treatment frequency could become meaningful for patients who otherwise remain on biologic therapy for years, particularly if less frequent dosing does not require sacrificing efficacy or safety.

The commercial proposition is therefore built around three attributes: complete clearance, durability and convenience. High PASI 100 rates can differentiate a treatment on efficacy, extended response duration can reduce disease recurrence between doses, and long intervals between injections can lower treatment burden.

However, Oruka Therapeutics still needs to demonstrate that those advantages remain reproducible in substantially larger populations. EVERLAST-A began with only 63 patients receiving active treatment from baseline, meaning a small number of outcomes can materially influence percentage response rates.

Cross-trial comparisons also require restraint. Different psoriasis trials use different patient populations, prior-treatment histories, analysis methods and missing-data assumptions. The current ORKA-001 results therefore cannot establish superiority over Skyrizi, Tremfya or other established therapies without direct comparative evidence.

The more important question for Phase 3 may ultimately be whether ORKA-001 can achieve a sufficiently differentiated dosing profile while performing at least as strongly as existing IL-23 therapies on efficacy and safety. That combination could create a compelling market entry even without proving statistical superiority over every competitor.

EVERLAST-B and 52-week data now become critical tests before Oruka begins Phase 3

The next several months contain two important readouts that should provide considerably more evidence about ORKA-001’s commercial profile. EVERLAST-B, the company’s Phase 2b dose-ranging trial, has completed enrollment of 187 patients. The study is evaluating several induction regimens and is expected to report Week 16 results during the fourth quarter. Those findings are intended to guide dose selection for the Phase 3 program that Oruka Therapeutics expects to begin during the first half of 2027.

The study is also designed to test longer-term maintenance strategies. Patients who achieve PASI 100 can be evaluated under extended dosing intervals, allowing Oruka Therapeutics to further examine whether annual or twice-yearly treatment can maintain complete clearance.

Full Week 52 EVERLAST-A results are expected in December. Those data may be even more important for the company’s differentiation thesis because they will show whether responses remain durable approximately one year after study initiation and how many patients can sustain deep skin clearance with very limited additional therapy.

A strong Week 52 result would provide more compelling evidence that ORKA-001’s extended half-life translates into durable disease control rather than simply delayed loss of response. Weakening clearance before the one-year mark, however, could make twice-yearly dosing more realistic than annual administration.

Safety will also receive greater scrutiny as exposure increases. ORKA-001 remained generally well tolerated through Week 28, with upper respiratory tract infection the only treatment-emergent adverse event reported in at least 5% of treated patients during the latest period. Two serious adverse events occurred, involving a tibial fracture and prostate adenocarcinoma, but neither was considered treatment-related. No injection-site reactions were reported. That profile remains consistent with the established IL-23 class so far, but larger Phase 3 studies will be required to identify less common adverse events and confirm that the half-life extension technology does not create additional long-term safety concerns.

Oruka’s $1.1 billion cash position supports Phase 3 while rising valuation raises the performance bar

Oruka Therapeutics is unusually well funded for a company approaching its first Phase 3 program. The company held approximately $1.1 billion in cash, cash equivalents and marketable securities at the end of the second quarter after completing an upsized $700 million public offering earlier in the year. Management expects those resources to fund operations through an anticipated Biologics License Application for ORKA-001 while continuing development of ORKA-002.

That financial position materially reduces near-term dilution risk and allows Oruka Therapeutics to plan Phase 3 development without depending immediately on another capital raise or a large pharmaceutical partner. Research and development expenses reached $43.3 million in the second quarter, up from $24.1 million a year earlier as clinical programs expanded. General and administrative expenses also increased to $6.9 million. Spending should rise further once the ORKA-001 Phase 3 program begins, but the company’s existing resources provide considerable flexibility.

The broader pipeline adds further optionality. ORKA-002 is being developed across psoriasis and hidradenitis suppurativa, while ORKA-004 targets TL1A and is expected to enter clinical testing. Oruka Therapeutics also expanded its license rights with Paragon Therapeutics to include inflammatory bowel disease, potentially widening the long-term use of ORKA-001 beyond dermatology.

Investors have already assigned substantial value to those possibilities. Oruka Therapeutics’ market capitalization stood near $5.66 billion during afternoon trading, an increase of more than 580% over the previous year. The share price fell around 9.6% to approximately $85.50 during the session despite the positive Week 28 update.

The decline appears less related to an obvious clinical disappointment than to heightened expectations. ORKA-001 had already produced strong Week 16 results, and the company had repeatedly emphasized the potential for responses to deepen through Week 28. A substantial share-price rally ahead of the release therefore left a high threshold for additional upside. Market coverage characterized the move as a possible sell-the-news reaction following the anticipated positive durability result.

That valuation makes the upcoming catalysts especially important. A company valued at several billion dollars before Phase 3 is already reflecting meaningful expectations of eventual commercial success. EVERLAST-B and Week 52 data will need to reinforce not only that ORKA-001 works, but that it offers enough differentiation to justify competing against some of the strongest existing biologics in dermatology.

The latest results move Oruka Therapeutics closer to that objective. Complete skin clearance continued to deepen months after treatment stopped, supporting the idea that extended IL-23 inhibition could meaningfully change the dosing burden associated with psoriasis biologics. The next test is whether that profile persists through one year and scales across larger studies as ORKA-001 approaches pivotal development.

Key takeaways from ORKA-001 Week 28 durability data and Oruka Therapeutics’ Phase 3 strategy

• ORKA-001 achieved PASI 100 in 71.4% of patients at Week 28, up from 63.5% at Week 16.
• PASI 90 increased to 87.3% even though patients received no additional ORKA-001 after Week 4.
• The continued improvement supports Oruka Therapeutics’ strategy of developing ORKA-001 for once- or twice-yearly maintenance dosing.
• ORKA-001 targets the validated IL-23p19 pathway while using half-life extension technology to remain in circulation substantially longer.
• Existing psoriasis biologics such as Tremfya and Skyrizi require maintenance injections every eight or 12 weeks, creating an opportunity for less frequent dosing if ORKA-001 maintains competitive efficacy.
• The Phase 2a dataset remains relatively small, meaning larger studies are necessary before comparative efficacy conclusions can be drawn.
• EVERLAST-B has enrolled 187 patients, with Week 16 results expected during the fourth quarter to support Phase 3 dose selection.
• Full Week 52 EVERLAST-A results expected in December will provide a more important test of the durability and annual-dosing thesis.
• Oruka Therapeutics held approximately $1.1 billion in cash and investments and expects its resources to fund operations through a potential ORKA-001 BLA filing.
• Oruka Therapeutics shares fell sharply despite the positive data as investors weighed strong clinical results against a valuation already reflecting substantial expectations.